Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3027) 3027
Publication (265) 265
Newsletter (80) 80
Newspaper Article (62) 62
Book Review (55) 55
Book Chapter (25) 25
Book / eBook (17) 17
Magazine Article (8) 8
Dissertation (3) 3
Conference Proceeding (2) 2
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2474) 2474
pneumonia (1564) 1564
index medicus (1306) 1306
male (1151) 1151
female (1091) 1091
anti-bacterial agents - therapeutic use (991) 991
staphylococcal infections - drug therapy (747) 747
infectious diseases (742) 742
staphylococcus aureus (730) 730
adult (688) 688
middle aged (675) 675
bacterial pneumonia (664) 664
microbiology (619) 619
aged (587) 587
pneumonia, staphylococcal - drug therapy (564) 564
infections (563) 563
antibiotics (548) 548
staphylococcal infections - microbiology (441) 441
health aspects (434) 434
pharmacology & pharmacy (421) 421
staphylococcus aureus - drug effects (401) 401
animals (392) 392
risk factors (391) 391
child (381) 381
adolescent (359) 359
mortality (359) 359
anti-bacterial agents - pharmacology (352) 352
microbial sensitivity tests (352) 352
vancomycin (340) 340
ventilator-associated pneumonia (338) 338
drug resistance in microorganisms (327) 327
staphylococcus aureus infections (321) 321
pneumonia - drug therapy (320) 320
staphylococcus infections (320) 320
treatment outcome (320) 320
methicillin resistance (319) 319
research (301) 301
cross infection - drug therapy (295) 295
methicillin-resistant staphylococcus aureus (294) 294
drug resistance (289) 289
infant (286) 286
bacteria (284) 284
child, preschool (283) 283
community-acquired pneumonia (283) 283
epidemiology (277) 277
nosocomial infections (275) 275
bacteremia (265) 265
staphylococcal infections (264) 264
methicillin-resistant staphylococcus aureus - drug effects (262) 262
retrospective studies (262) 262
immunology (250) 250
infection (249) 249
care and treatment (248) 248
pneumonia, staphylococcal - microbiology (247) 247
resistant staphylococcus-aureus (247) 247
panton-valentine leukocidin (245) 245
respiratory system (245) 245
mrsa (242) 242
community-acquired infections - microbiology (241) 241
anti-bacterial agents - administration & dosage (239) 239
drug therapy (233) 233
pneumonia, bacterial - drug therapy (232) 232
methicillin-resistant staphylococcus aureus - isolation & purification (231) 231
cross infection - microbiology (229) 229
staphylococcal infections - epidemiology (222) 222
aged, 80 and over (221) 221
community-acquired infections - drug therapy (220) 220
pediatrics (215) 215
mice (214) 214
linezolid (212) 212
medicine, general & internal (211) 211
staphylococcus aureus - isolation & purification (209) 209
analysis (203) 203
internal medicine (202) 202
hospitals (201) 201
diagnosis (199) 199
children (198) 198
nosocomial pneumonia (197) 197
vancomycin - therapeutic use (197) 197
cross infection (196) 196
methicillin-resistant (192) 192
pathogens (186) 186
pneumonia, bacterial - microbiology (181) 181
medicine (179) 179
sepsis (178) 178
therapy (170) 170
antibacterial agents (168) 168
patients (166) 166
bacterial infections - drug therapy (165) 165
critical care medicine (164) 164
drug resistance, bacterial (163) 163
methicillin (161) 161
infectious disease (160) 160
prospective studies (158) 158
intensive care units (154) 154
research article (154) 154
risk-factors (154) 154
staphylococcus-aureus (154) 154
bacterial infections (152) 152
antimicrobial agents (149) 149
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2877) 2877
Russian (99) 99
German (53) 53
French (47) 47
Japanese (45) 45
Spanish (30) 30
Polish (17) 17
Chinese (14) 14
Italian (10) 10
Romanian (7) 7
Portuguese (4) 4
Ukrainian (4) 4
Danish (2) 2
Dutch (2) 2
Korean (2) 2
Lithuanian (2) 2
Norwegian (2) 2
Swedish (2) 2
Turkish (2) 2
Afrikaans (1) 1
Finnish (1) 1
Hebrew (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Linezolid in Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia: A Randomized, Controlled Study
by Richard G. Wunderink and Michael S. Niederman and Marin H. Kollef and Andrew F. Shorr and Mark J. Kunkel and Alice Baruch and William T. McGee and Arlene Reisman and Jean Chastre
Clinical Infectious Diseases, ISSN 1058-4838, 3/2012, Volume 54, Issue 5, pp. 621 - 629
Background. Post hoc analyses of clinical trial data suggested that linezolid may be more effective than vancomycin for treatment of methicillin-resistant... 
Staphylococcal pneumonia | Pneumonia | Health outcomes | Mortality | Methicillin resistant staphylococcus aureus | Ventilator associated pneumonia | Infections | ARTICLES AND COMMENTARIES | Nephrotoxicity | Staphylococcus aureus | Artificial respiration | UNITED-STATES | INFECTIOUS DISEASES | HOSPITALIZED-PATIENTS | INFECTIONS | MULTICENTER | VANCOMYCIN | VENTILATOR-ASSOCIATED PNEUMONIA | CARE-ASSOCIATED PNEUMONIA | DOUBLE-BLIND | MICROBIOLOGY | IMMUNOLOGY | EPIDEMIOLOGY | Linezolid | Humans | Methicillin-Resistant Staphylococcus aureus - drug effects | Middle Aged | Cross Infection - mortality | Male | Oxazolidinones - adverse effects | Treatment Outcome | Oxazolidinones - administration & dosage | Pneumonia, Staphylococcal - microbiology | Cross Infection - drug therapy | Oxazolidinones - therapeutic use | Anti-Bacterial Agents - therapeutic use | Pneumonia, Staphylococcal - drug therapy | Acetamides - therapeutic use | Pneumonia, Staphylococcal - mortality | Cross Infection - microbiology | Acetamides - adverse effects | Adult | Female | Aged | Anti-Bacterial Agents - adverse effects | Anti-Bacterial Agents - administration & dosage | Acetamides - administration & dosage | Usage | Ventilator-associated pneumonia | Patient outcomes | Research | Drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Continued emergence of USA300 methicillin-resistant staphylococcus aureus in the United States: Results from a nationwide surveillance study
by Diekema, Daniel J and Richter, Sandra S and Heilmann, Kristopher P and Dohrn, Cassie L and Riahi, Fathollah and Tendolkar, Shailesh and Mcdanel, Jennifer S and Doern, Gary V
Infection Control and Hospital Epidemiology, ISSN 0899-823X, 03/2014, Volume 35, Issue 3, pp. 285 - 292
Background.The epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) is changing, with USA300 emerging first in community and then in healthcare... 
INFECTIOUS DISEASES | INFECTIONS | AMERICA | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | MEC | FITNESS COST | REGION | United States - epidemiology | Pneumonia, Staphylococcal - epidemiology | Humans | Middle Aged | Child, Preschool | Infant | Male | Pneumonia, Staphylococcal - microbiology | Methicillin-Resistant Staphylococcus aureus | Microbial Sensitivity Tests | Young Adult | Adult | Female | Staphylococcal Infections - microbiology | Wound Infection - drug therapy | Child | Infant, Newborn | Cross Infection - epidemiology | Staphylococcal Infections - drug therapy | Cross Infection - drug therapy | Wound Infection - epidemiology | Pneumonia, Staphylococcal - drug therapy | Staphylococcal Infections - epidemiology | Molecular Epidemiology | Cross Infection - microbiology | Adolescent | Wound Infection - microbiology | Aged | Population Surveillance
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Assessment of an Anti-Alpha-Toxin Monoclonal Antibody for Prevention and Treatment of Staphylococcus aureus-Induced Pneumonia
by L. Hua and J. J. Hilliard and Y. Shi and C. Tkaczyk and L. I. Cheng and X. Yu and V. Datta and S. Ren and H. Feng and R. Zinsou and A. Keller and T. O'Day and Q. Du and L. Cheng and M. Damschroder and G. Robbie and J. Suzich and C. K. Stover and B. R. Sellman
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 02/2014, Volume 58, Issue 2, pp. 1108 - 1117
Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit... 
MURINE MODEL | PSEUDOMONAS-AERUGINOSA | MOUSE MODEL | HUMAN-IGG | ACUTE LUNG INJURY | SKIN INFECTION | RABBIT MODEL | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | CELL-ADHESION | HEMOLYSIN | VIRULENCE | Linezolid | Lung - microbiology | Hemolysin Proteins - immunology | Kidney - immunology | Acetamides - pharmacology | Hemolysin Proteins - antagonists & inhibitors | Pneumonia, Staphylococcal - microbiology | Bacterial Toxins - antagonists & inhibitors | Chemokines - antagonists & inhibitors | Vancomycin - pharmacology | Female | Drug Therapy, Combination | Pneumonia, Staphylococcal - immunology | Staphylococcus aureus - metabolism | Chemokines - biosynthesis | Kidney - drug effects | Antibodies, Monoclonal - pharmacology | Bacterial Toxins - immunology | Mice, Inbred C57BL | Drug Synergism | Kidney - microbiology | Pneumonia, Staphylococcal - drug therapy | Animals | Pneumonia, Staphylococcal - mortality | Oxazolidinones - pharmacology | Lung - drug effects | Survival Analysis | Immunization, Passive | Anti-Bacterial Agents - pharmacology | Mice | Bronchoalveolar Lavage Fluid - chemistry | Staphylococcus aureus - drug effects | Lung - immunology | Experimental Therapeutics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Effects of Linezolid on Suppressing In Vivo Production of Staphylococcal Toxins and Improving Survival Outcomes in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Necrotizing Pneumonia
by Binh An Diep and Anna Afasizheva and Hoan N. Le and Osamu Kajikawa and Gustavo Matute-Bello and Christine Tkaczyk and Bret Sellman and Cedric Badiou and Gerard Lina and Henry F. Chambers
The Journal of Infectious Diseases, ISSN 0022-1899, 7/2013, Volume 208, Issue 1, pp. 75 - 82
Background. Linezolid is recommended for treatment of pneumonia and other invasive infections caused by methicillin-resistant Staphylococcus aureus (MRSA). The... 
Rabbits | Staphylococcal pneumonia | Pneumonia | Health outcomes | BACTERIA | Lungs | Methicillin resistant staphylococcus aureus | Infections | Toxins | Leukocidins | Staphylococcus aureus | Panton-Valentine leukocidin | treatment | linezolid | rabbit model | pneumonia | MRSA | vancomycin | protein synthesis inhibitor | alpha-hemolysin | INFECTIOUS DISEASES | COMMUNITY-ACQUIRED PNEUMONIA | INFECTIONS | ANTIBIOTICS | EFFICACY | MICROBIOLOGY | IMMUNOLOGY | VIRULENCE | GENES | DOUBLE-BLIND | CLOSTRIDIUM-PERFRINGENS | Linezolid | Bacterial Toxins - analysis | Methicillin-Resistant Staphylococcus aureus - drug effects | Lung - chemistry | Pneumonia, Staphylococcal - microbiology | Interleukin-8 - analysis | Bacterial Load - drug effects | Oxazolidinones - therapeutic use | Bacterial Toxins - antagonists & inhibitors | Anti-Bacterial Agents - therapeutic use | Bacterial Toxins - biosynthesis | Pneumonia, Staphylococcal - drug therapy | Animals | Acetamides - therapeutic use | Pneumonia, Staphylococcal - mortality | Vancomycin - therapeutic use | Leukocidins - analysis | Exotoxins - analysis | Hemolysin Proteins - analysis | Chemokine CCL2 - analysis | Disease Models, Animal | Exotoxins | Patient outcomes | Bacterial pneumonia | Staphylococcus aureus infections | Models | Dosage and administration | Research | Drug therapy | Major and Brief Reports
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text The Role of Vancomycin in the Treatment Paradigm
by Dennis L. Stevens
Clinical Infectious Diseases, ISSN 1058-4838, 1/2006, Volume 42, Issue 1, pp. S51 - S57
Vancomycin was introduced in the United States in 1956 as a possible treatment for infections due to penicillin-resistant Staphylococcus aureus, but it was not... 
Staphylococcal pneumonia | Antibacterials | Antibiotics | Endocarditis | Infections | Ventilator associated pneumonia | Dosage | Staphylococcus aureus | Bacteremia | Staphylococcus | SOFT-TISSUE INFECTIONS | INFECTIOUS DISEASES | VENTILATOR-ASSOCIATED PNEUMONIA | ANTIMICROBIAL THERAPY | LINEZOLID PNU-100766 | MICROBIOLOGY | IMMUNOLOGY | RESISTANT STAPHYLOCOCCUS-AUREUS | COMPLICATED SKIN | IN-VITRO | GRAM-POSITIVE INFECTIONS | DOUBLE-BLIND | ENDOCARDITIS | Endocarditis, Bacterial - drug therapy | Staphylococcal Infections - drug therapy | Anti-Bacterial Agents - blood | Humans | Bacteremia - complications | Bacteremia - drug therapy | Staphylococcal Infections - complications | Endocarditis, Bacterial - complications | Vancomycin - blood | Bacteremia - microbiology | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Pneumonia, Staphylococcal - drug therapy | Staphylococcal Skin Infections - drug therapy | Soft Tissue Infections - microbiology | Vancomycin - therapeutic use | Treatment Failure | Vancomycin - pharmacology | Endocarditis, Bacterial - microbiology | Anti-Bacterial Agents - pharmacology | Soft Tissue Infections - drug therapy | Drug Therapy, Combination | Staphylococcus aureus - drug effects | Staphylococcal Skin Infections - microbiology | Vancomycin | Drug therapy | Health aspects | Staphylococcal infections
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens
by Ethan Rubinstein and Tahaniyat Lalani and G. Ralph Corey and Zeina A. Kanafani and Esteban C. Nannini and Marcelo G. Rocha and Galia Rahav and Michael S. Niederman and Marin H. Kollef and Andrew F. Shorr and Patrick C. Lee and Arnold L. Lentnek and Carlos M. Luna and Jean-Yves Fagon and Antoni Torres and Michael M. Kitt and Fredric C. Genter and Steven L. Barriere and H. David Friedland and Martin E. Stryjewski and ATTAIN Study Group and for the ATTAIN Study Group
Clinical Infectious Diseases, ISSN 1058-4838, 1/2011, Volume 52, Issue 1, pp. 31 - 40
Background. Telavancin is a lipoglycopeptide bactericidal against gram-positive pathogens. Methods. Two methodologically identical, double-blind studies (0015... 
Pathogens | Pneumonia | Infectious diseases | Antibiotics | Medications | Cultural groups | Infections | Ventilator associated pneumonia | ARTICLES AND COMMENTARIES | Medical cures | Staphylococcus aureus | Double-Blind Method | Humans | Methicillin-Resistant Staphylococcus aureus - drug effects | Middle Aged | Male | Treatment Outcome | Pneumonia, Staphylococcal - microbiology | Lipoglycopeptides | Cross Infection - drug therapy | Anti-Bacterial Agents - therapeutic use | Pneumonia, Staphylococcal - drug therapy | Vancomycin - therapeutic use | Cross Infection - microbiology | Aged, 80 and over | Adult | Female | Aged | Methicillin-Resistant Staphylococcus aureus - isolation & purification | Aminoglycosides - therapeutic use | Usage | Bacterial pneumonia | Gram-positive bacteria | Cross infection | Nosocomial infections | Vancomycin | Drug therapy | Health aspects | Risk factors | and Commentaries
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Statins Enhance Formation of Phagocyte Extracellular Traps
by Chow, Ohn A and von Köckritz-Blickwede, Maren and Bright, A. Taylor and Hensler, Mary E and Zinkernagel, Annelies S and Cogen, Anna L and Gallo, Richard L and Monestier, Marc and Wang, Yanming and Glass, Christopher K and Nizet, Victor
Cell Host & Microbe, ISSN 1931-3128, 2010, Volume 8, Issue 5, pp. 445 - 454
Statins are inhibitors of 3-hydroxy 3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in cholesterol biosynthesis. Recent... 
MACROPHAGES | MICROBIOLOGY | STAPHYLOCOCCUS-AUREUS PNEUMONIA | IMPROVES SURVIVAL | SEPSIS | CELL-DEATH | MURINE MODEL | VIROLOGY | GROUP-A STREPTOCOCCUS | MICE | PRAVASTATIN | SIMVASTATIN | PARASITOLOGY | Acyl Coenzyme A - antagonists & inhibitors | Humans | DNA, Bacterial - immunology | Male | Pneumonia, Staphylococcal - microbiology | DNA, Bacterial - drug effects | Extracellular Space - metabolism | Neutrophils - microbiology | Macrophages - immunology | Macrophages - microbiology | Pneumonia, Staphylococcal - immunology | Mice, Inbred CFTR | Phagocytes - drug effects | Mice, Inbred C57BL | Neutrophils - drug effects | Cells, Cultured | Neutrophils - immunology | Phagocytes - immunology | Extracellular Space - immunology | Pneumonia, Staphylococcal - drug therapy | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Extracellular Space - microbiology | Phagocytes - microbiology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Macrophages - drug effects | Mice | Staphylococcus aureus - drug effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients
by Lin, Jennifer C and Fierer, Joshua and Aung, Gregory and Johns, Scott and Thomas, Amy and Jahng, Maximillian
Journal of Infection and Chemotherapy, ISSN 1341-321X, 2013, Volume 19, Issue 1, pp. 42 - 49
Abstract There are many limitations to the current antibiotics used for the treatment of severe methicillin-resistant Staphylococcus aureus (MRSA) infections.... 
Hematology, Oncology and Palliative Medicine | Osteomyelitis | Medical Microbiology | Medicine & Public Health | Ceftaroline | Endocarditis | Infectious Diseases | Methicillin-resistant Staphylococcus aureus (MRSA) | Bacteremia | Virology | INFECTIOUS DISEASES | PHASE-III | PHARMACOLOGY & PHARMACY | COMPLICATED SKIN | Arthritis, Infectious - drug therapy | Humans | Middle Aged | Male | Pneumonia, Staphylococcal - microbiology | Arthritis, Infectious - microbiology | Osteomyelitis - drug therapy | Bacteremia - microbiology | Cephalosporins - therapeutic use | Anti-Bacterial Agents - therapeutic use | Aged, 80 and over | Endocarditis, Bacterial - microbiology | Adult | Female | Retrospective Studies | Staphylococcal Infections - microbiology | Endocarditis, Bacterial - drug therapy | Staphylococcal Infections - drug therapy | Methicillin-Resistant Staphylococcus aureus - drug effects | Bacteremia - drug therapy | Treatment Outcome | Pneumonia, Staphylococcal - drug therapy | Osteomyelitis - microbiology | Aged | Prodrugs - therapeutic use | Moxalactam | Drug resistance in microorganisms | Pneumonia | Usage | Prosthesis | Bacterial pneumonia | Staphylococcus aureus infections | Drugstores | Cephalosporins | Implants, Artificial | Cephaloridine | Health aspects | Staphylococcus aureus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Effects of tedizolid phosphate on survival outcomes and suppression of production of staphylococcal toxins in a rabbit model of methicillin-resistant Staphylococcus aureus necrotizing pneumonia
by Le, Vien T.M and Le, Hoan N and Pinheiro, Marcos Gabriel and Hahn, Kenneth J and Dinh, Mary L and Larson, Kajal B and Flanagan, Shawn D and Badiou, Cedric and Lina, Gerard and Tkaczyk, Christine and Sellman, Bret R and Diep, Binh An
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 04/2017, Volume 61, Issue 4
The protective efficacy of tedizolid phosphate, a novel oxazolidinone that potently inhibits bacterial protein synthesis, was compared to those of linezolid,... 
Linezolid | Pneumonia | Alpha-toxin | PVL | Rabbit model | Vancomycin | Tedizolid | STRAINS | ANTIBIOTICS | MICROBIOLOGY | USA300 | VIRULENCE | linezolid | SUBINHIBITORY CONCENTRATIONS | rabbit model | ACUTE BACTERIAL SKIN | pneumonia | SKIN-STRUCTURE INFECTIONS | alpha-toxin | vancomycin | PHARMACOLOGY & PHARMACY | ENDOCARDITIS | tedizolid | EXPRESSION | Rabbits | Linezolid - therapeutic use | Methicillin-Resistant Staphylococcus aureus - drug effects | Pneumonia, Necrotizing - drug therapy | Organophosphates - therapeutic use | Pneumonia, Staphylococcal - microbiology | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Methicillin-Resistant Staphylococcus aureus - metabolism | Pneumonia, Staphylococcal - drug therapy | Animals | Vancomycin - therapeutic use | Anti-Bacterial Agents - pharmacology | Staphylococcus aureus - drug effects | Oxazoles - therapeutic use | Pneumonia, Necrotizing - microbiology | Staphylococcus aureus - metabolism | Life Sciences | Microbiology and Parasitology | Immunology | Bacteriology | Virology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: Specific evaluation of vancomycin pharmacokinetic indices
by Jeffres, Meghan N and Isakow, Warren and Doherty, Joshua A and McKinnon, Peggy S and Ritchie, David J and Micek, Scott T and Kollef, Marin H
Chest, ISSN 0012-3692, 2006, Volume 130, Issue 4, pp. 947 - 955
Objective: The goal of this investigation was to determine whether vancomycin pharmacokinetie indexes (eg, serum trough concentrations or area under the... 
Pneumonia | Methicillin resistance | Antibiotics | Staphylococcus aureus | UNITED-STATES | methicillin resistance | INFECTIONS | VENTILATOR-ASSOCIATED PNEUMONIA | TREATMENT OUTCOMES | SUSCEPTIBILITY | ANTIMICROBIALS | THERAPY | pneumonia | PANTON-VALENTINE LEUKOCIDIN | RESPIRATORY SYSTEM | BACTEREMIA | antibiotics | EPIDEMIOLOGY | Area Under Curve | Humans | Middle Aged | Cross Infection - mortality | Biological Availability | Male | Dose-Response Relationship, Drug | Missouri | Adult | Female | Retrospective Studies | Methicillin Resistance | Vancomycin - administration & dosage | Drug Administration Schedule | Hospital Mortality | Pneumonia, Staphylococcal - blood | Risk Factors | Treatment Outcome | Cross Infection - drug therapy | Pneumonia, Staphylococcal - drug therapy | Pneumonia, Staphylococcal - mortality | Vancomycin - pharmacokinetics | Anti-Bacterial Agents - pharmacokinetics | Survival Analysis | Aged | Staphylococcus aureus - drug effects | Anti-Bacterial Agents - administration & dosage | Cross Infection - blood | Cohort Studies
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Time Course and Extent of Renal Function Changes in Patients Receiving Treatment for Staphylococcal Pneumonias: An Analysis Comparing Telavancin and Vancomycin from the ATTAIN Trials
by Nogid, Boris and Lacy, Melinda K and Jacobs, Micah and Bruss, Jon and Dwyer, Jamie
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, ISSN 0277-0008, 10/2018, Volume 38, Issue 10, pp. 990 - 998
Study Objective Telavancin and vancomycin are both approved for treatment of hospital‐acquired and ventilator‐associated bacterial pneumonias caused by... 
vancomycin | renal function | telavancin | pneumonia | Staphylococcus aureus | Vancomycin - administration & dosage | Humans | Middle Aged | Lipoglycopeptides - administration & dosage | Male | Healthcare-Associated Pneumonia - drug therapy | Kidney Function Tests | Randomized Controlled Trials as Topic | Vancomycin - adverse effects | Creatinine - metabolism | Lipoglycopeptides - adverse effects | Clinical Trials, Phase III as Topic | Pneumonia, Staphylococcal - drug therapy | Aminoglycosides - administration & dosage | Time Factors | Adult | Female | Aged | Anti-Bacterial Agents - adverse effects | Retrospective Studies | Aminoglycosides - adverse effects | Anti-Bacterial Agents - administration & dosage | Pneumonia, Ventilator-Associated - drug therapy | PULMONARY SURFACTANT | PIPERACILLIN-TAZOBACTAM | VENTILATOR-ASSOCIATED PNEUMONIA | HOSPITAL-ACQUIRED PNEUMONIA | CLINICAL-PRACTICE GUIDELINES | KIDNEY INJURY | PHARMACOLOGY & PHARMACY | EPITHELIAL LINING FLUID | AUREUS | INDUCED NEPHROTOXICITY | INFECTIOUS-DISEASES SOCIETY | Pneumonia | Bacterial pneumonia | Analysis | Staphylococcal infections | Clinical trials | Vancomycin | Drug therapy | Creatinine | Ventilators | Renal function | Statistical analysis | Safety engineering | Data processing | Adults | Patients | Original | Original s
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Efficacy of Ceftaroline Fosamil in a Staphylococcal Murine Pneumonia Model
by Amira A. Bhalodi and Jared L. Crandon and Donald Biek and David P. Nicolau
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 12/2012, Volume 56, Issue 12, pp. 6160 - 6165
Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit... 
INFECTIONS | STREPTOCOCCUS-PNEUMONIAE | VANCOMYCIN | THIGH | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | AUREUS | PHARMACODYNAMICS | OUTCOMES | Lung - microbiology | Humans | Colony Count, Microbial | Pneumonia, Staphylococcal - microbiology | Methicillin-Resistant Staphylococcus aureus | Dose-Response Relationship, Drug | Microbial Sensitivity Tests | Neutropenia - complications | Anti-Bacterial Agents - therapeutic use | Pneumonia, Staphylococcal - drug therapy | Animals | Anti-Bacterial Agents - pharmacokinetics | Protein Binding | Female | Mice | Mice, Inbred BALB C | Immunocompromised Host | Anti-Bacterial Agents - administration & dosage | Cephalosporins - pharmacology | Clinical Therapeutics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Emergence of community-acquired meticillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotising community-onset pneumonia
by Hidron, Alicia I, MD and Low, Cari E, MD and Honig, Eric G, MD and Blumberg, Henry M, MD
Lancet Infectious Diseases, The, ISSN 1473-3099, 2009, Volume 9, Issue 6, pp. 384 - 392
Summary Meticillin-resistant Staphylococcus aureus (MRSA), usually known as a nosocomial pathogen, has emerged as the predominant cause of skin and soft-tissue... 
Infectious Disease | UNITED-STATES | INFECTIOUS DISEASES | IN-VITRO | INFLUENZA-A | PROTEIN-A | SUBINHIBITORY CONCENTRATIONS | VANCOMYCIN THERAPY | PANTON-VALENTINE LEUKOCIDIN | TOXIC-SHOCK-SYNDROME | CASSETTE CHROMOSOME MEC | NOSOCOMIAL PNEUMONIA | United States | Humans | Middle Aged | Male | Pneumonia, Staphylococcal - microbiology | Pneumonia, Staphylococcal - physiopathology | Anti-Bacterial Agents - therapeutic use | Penicillin-Binding Proteins | Community-Acquired Infections - drug therapy | Communicable Diseases, Emerging - drug therapy | Adult | Bacterial Toxins - genetics | Female | Methicillin-Resistant Staphylococcus aureus - genetics | Communicable Diseases, Emerging - physiopathology | Leukocidins - genetics | Communicable Diseases, Emerging - microbiology | Bacterial Proteins - genetics | Genotype | Virulence Factors | Clindamycin - therapeutic use | Pneumonia, Staphylococcal - drug therapy | Exotoxins - genetics | Methicillin-Resistant Staphylococcus aureus - isolation & purification | Community-Acquired Infections - physiopathology | Drug Resistance, Multiple, Bacterial - genetics | Intubation, Intratracheal | Community-Acquired Infections - microbiology | Medical colleges | Pneumonia | Bacterial pneumonia | Staphylococcus aureus infections | Cross infection | Nosocomial infections | Staphylococcus aureus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights